Company intelligence / Profile preview

Apeiron Investment Group

Sliema, Tas-Sliema, Malta

Ownership: Private
Employees: ~96
Development stage: Other

Overview

Apeiron Investment Group is a family office and discretionary investment firm managing approximately $7 billion, founded and led by Christian Angermayer, with substantial investments in the biotech, psychedelic mental health, and life science sectors (notably including ATAI Life Sciences and other mental health therapeutics platforms).

Modalities: small moleculesbiologicspsychedelic compounds
Industry: Investors

Partnerships

Invested in and closely involved with ATAI Life Sciences (publicly listed biotech advancing psychedelic-based and next-generation mental health treatments)Anchor investments in companies like Rejuveron Life Sciences and Juvenescence (longevity and biotech focus)Partnerships often via portfolio companies, not direct corporate partnerships.

Beyond the preview

Go deeper on Apeiron Investment Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apeiron Investment Group.

Explore the full profile